Search Results - subject:"Sodium-aurothiomalate"

Modelling Cost Effectiveness and Cost Utility of Sequential DMARD Therapy Including Leflunomide for Rheumatoid Arthritis in Germany: II. The Contribution of Leflunomide to Efficiency

Schadlich, Peter K.; Zeidler, Henning; Zink, Angela; … - In: PharmacoEconomics 23 (2005) 4, pp. 395-420

Objective: To estimate the 3-year incremental cost effectiveness and cost utility of introducing leflunomide into sequential therapy, consisting of the most frequently used disease-modifying antirheumatic drugs (DMARDs), for patients with rheumatoid arthritis in specialised, i.e....

Persistent link: https://www.econbiz.de/10005590474

Modelling Cost Effectiveness and Cost Utility of Sequential DMARD Therapy Including Leflunomide in Rheumatoid Arthritis in Germany: I. Selected DMARDs and Patient-Related Costs

Schadlich, Peter K.; Zeidler, Henning; Zink, Angela; … - In: PharmacoEconomics 23 (2005) 4, pp. 377-393

adverse drug reactions (ADRs) were highest for intramuscular gold (sodium aurothiomalate) [_2106 (_1 ~= $US0.91; average of …

Persistent link: https://www.econbiz.de/10005590526